Between March 14-16th, 2016 in Tepoztlan, Mexico, the 2016 Global Ibogaine Conference will convene experts from around the world to discuss ibogaine therapy, the climate of global drug policy, and the sustainability and traditional uses of Tabernanthe iboga.
Since the 1980s ibogaine, the primary psychoactive extract of T. iboga, has increasingly been used experimentally in the detoxification from opiates and as a treatment for substance use disorders. Early clinical trials confirmed some very promising initial reports, but were later suspended because of funding and litigation. Ibogaine’s use has continued to grow, from the early peer-to-peer drug user networks, to today when ibogaine is administered under compassionate access or experimental legal frameworks in some progressive hospitals, medical centers, retreats, and private therapeutic practices around the world.
The landscape of ibogaine research and practice has changed dramatically. However, ibogaine’s continued promotion as a ‘cure for addiction’ overemphasizes its potential as a stand-alone therapy while contemporary understandings of addictions address a complex biological, psychological and social foundations of addictive behavior. This conference will bring refreshing voices from across the spectrum of traditional practice, medicine, psychology, harm reduction and drug policy in order to advance the use of ibogaine in a comprehensive therapeutic framework.
Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.
Thumbnail: Flickr CC Martin D